Pentoxyverin

Carbetapentane

HCID 2562CAS 77-23-6

Grundinformationen

Standard-SMILES
CCN(CC)CCOCCOC(=O)C1(c2ccccc2)CCCC1
InChIKey
CFJMRBQWBDQYMK-UHFFFAOYSA-N
Summenformel
C20H31NO3
Durchschnittliche Molmasse
333,5 g/mol
Monoisotopische Masse
333,23039385

Überblick

1-phenyl-1-cyclopentanecarboxylic acid 2-[2-(diethylamino)ethoxy]ethyl ester is a member of benzenes.

Namen und Bezeichner

Bevorzugter Name
Carbetapentane
IUPAC
2-[2-(diethylamino)ethoxy]ethyl 1-phenylcyclopentane-1-carboxylate
Lokaler Name
Pentoxyverin
Englischer Name
Pentoxyverine
Summenformel
C20H31NO3
Molmasse
333.46

Namen und Synonyme

carbetapentanePentoxyverine77-23-6PentoxiverinPentoxyverinAtussilPentoxiverinaPentoxyverinumSedotussin1-Phenyl-1-cyclopentanecarboxylateUCB 2543DTXSID9022734
Weitere Namen anzeigen
PENTOXIFYLLINEUrexTuclasePentoxyverine Baseucb2543u.c.b.2543U.C.B. 2543
2-(2-Diethylaminoethoxy)ethyl 1-phenylcyclopentanecarboxylate2-(Diethylaminoethoxy)ethyl 1-phenyl-1-cyclopentanecarboxylate2-(Diethylaminoethoxy)ethyl 1-phenylcyclopentyl-1-carboxylate32C726X12W1-Phenylcyclopentane-1-carboxylic acid diethylaminoethoxyethyl esterEthanol, 2-(2-(diethylamino)ethoxy)-, 1-phenylcyclopentanecarboxylate (ester)DTXCID1027341-Phenylcyclopentanecarboxylic acid 2-(2-diethylaminoethoxy)ethyl ester

Datenbank-Bezeichner

CAS
77-23-6
PubChem CID
2562
DTXSID
DTXSID9022734
ChEMBL
CHEMBL73234
ChEBI
CHEBI:94484
UNII
32C726X12W
EC Number
201-014-1
Nikkaji
J4.198J

Eigenschaften

Berechnete Struktureigenschaften

XLogP
3,8
Polarare Oberfläche (TPSA)
38,8 Ų
H-Brücken-Donoren
0
H-Brücken-Akzeptoren
4
Frei drehbare Bindungen
11
Schwere Atome
24

Experimentelle und physikochemische Eigenschaften

Drugs · 2 Einträge

Pharmaceuticals

Pharmaceuticals -> Listed in ZINC15

SolubilitySOL IN ETHYL ALC /CITRATE/
Human DrugsPharmaceuticals
Boiling Point165-170 °C @ 0.01 MM OF HG
Melting Point90-95
Collision Cross Section175.5 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

Physikochemische Eigenschaften

Siedepunkt
165 · 165-170 °C (1.33Pa)
Dichte
1.048 · 1.048±0.06 g/cm3(Predicted)
Brechungsindex
1.499 · 1.4990-1.5010
storage temp.
Refrigerator
Löslichkeit
Dichloromethane (Slightly), Methanol (Slightly)
pka
9.69 · 9.69±0.25(Predicted)

Sicherheit und Regulatorisches

Gefahrenhinweise

Regulatory InformationChemical: Cyclopentanecarboxylic acid, 1-phenyl-, 2-[2-(diethylamino)ethoxy]ethyl ester
Other Safety InformationIMAP assessments - Cyclopentanecarboxylic acid, 1-phenyl-, 2-[2-(diethylamino)ethoxy]ethyl ester: Environment tier I assessment

Toxikologische Informationen

Human Toxicity ExcerptsDRYNESS OF MOUTH OR THROAT, FEELING OF TIGHTNESS IN CHEST, & SLIGHT DEGREE OF RESPIRATORY DEPRESSION...ALLERGIC DERMATITIS /ADVERSE EFFECT, ORAL/

Sicherheitsdaten

Toxizität
LD50 oral in rat: 150mg/kg
Giftige Stoffe Daten
77-23-6(Hazardous Substances Data)

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 2 Einträge

R - Respiratory system

QR - Respiratory system

Protein BindingNo pharmacokinetic data available.
Pharmacodynamics · 1 Eintrag

Pentoxyverine induces an antitussive action. In animal studies, intraperitoneal administration of pentoxyverine inhibited citric-acid-induced cough in guinea-pigs _in vivo_. Some mice and rat studies suggest that pentoxyverine may also exert anticonvulsant activities without inducing a protective effect from NMDA-induced lethality. Protective effects against maximal electroshock-induced seizures in a dose-related fashion was also observed following either intraperitoneal or oral administration. In hERG-transfected cells, pentoxyverine inhibited the outward current of the hERG ion channel with half-maximal inhibition concentrations (IC50) of 3.0 µM. In rats receiving intrathecal administration, pentoxyverine exhibited dose-dependent spinal blockade with a more sensory-selective action over motor blockade. It induced a spinal blockade with a more sensory/nociceptive-selective action over motor blockade compared to lidocaine.

Mechanism of Action · 2 Einträge

While the mechanism of antitussive action of pentoxyverine is not fully understood, it is thought to be mediated via sigma-1 receptors expressed in the central nervous system. Pentoxyverine acts as an agonist at sigma receptors with the Ki of 75±28 nM, as demonstrated in a competitive binding assay. The function of sigma receptors on cough suppressant activities is unclear, however these receptors are highly expressed in the nucleus tractus solitarius (NTS) of the brainstem where the afferent fibres first synapse. NTS is located very close to the cough centre in the brainstem thus may function as a ‘gate' for the cough reflex and allow sigma-1 receptor agonists to modulate afferent activity prior to reaching the cough center. It is suggested that highly lipophilic sigma-1 agonists may penetrate the CNS following systemic administration. When administered as aerosols, sigma-1 receptor agonists may temporarily act in the periphery to modulate cough by acting activate sigma receptors expressed in the lungs. However there is limited evidence of peripheral localization of the sigma agonists following aerosol administration and the ruling out of systemic exposure. The local anesthesia action of pentoxyverine may occur through inhibition of voltage-gated Na(+) currents.

NUMBER OF DRUGS ARE KNOWN TO REDUCE COUGH AS RESULT OF THEIR CENTRAL ACTIONS, ALTHOUGH EXACT MECHANISMS ARE STILL NOT ENTIRELY CLEAR. /NONOPIOID ANTITUSSIVES/

Biological Half-LifeThe half-life is 2.3 hours following oral dosing.
Metabolism/MetabolitesNo pharmacokinetic data available.

Verwendung und Herstellung

Uses · 2 Einträge

MEDICATION

Use (kg; approx.) in Germany (2009): >1000

Methods of ManufacturingMORREN, BRITISH PATENT 753,799 (1956).
Formulations/PreparationsCARBETAPENTANE CITRATE /PRC: WITH CITRATE 1:1, TOCLASE & TUCLASE/. SYRUP, 7.25 MG/5 ML. SYRUP 7.25 MG, WITH TERPIN HYDRATE 16.7 MG, & CHLOROFORM 2.5 MG/5 ML (TOCLASE EXPECTORANT).
Use ClassificationPharmaceuticals

Anwendungen

VerwendenCarbetapentane is an antitussive anticonvulsant sigma site agonist.

Anbieter50 Anbieter

湖北威德利化学试剂有限公司181-6332-1995 18062128043 · [email protected]
艾吉析科技(上海)有限公司17717235263 · [email protected]
合肥翰刚医药科技有限公司+8618062405514 · [email protected]
湖北金梭生物科技有限公司00123456789 · [email protected]
湖北海克斯生化有限公司17362916295; 17362916295 · [email protected]

Zugehörige Reaktionen

0

Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.

Verknüpfte Notizen

Wird geladen…